Clinical Trial Update: Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase III trial assessing SyB L-0501 with Rituximab in recurrent/relapsed diffuse large B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• SyB L-0501

Snippet

Sponsor: SymBio Pharmaceuticals | Conditions: Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL | Phase 3 | Status: COMPLETED